Annual Call for Submissions Open for the Incyte Ingenuity Award Program

- Now in its second year, the Incyte Ingenuity Award program will offer two awards – a new award up to $35,000 along with original award up to $100,000
- Visit [www.IncyteIngenuityAwards.com](http://www.IncyteIngenuityAwards.com) to apply now

WILMINGTON, Del. – February 24, 2021 – The application process for Incyte’s second annual Open Call is open for submissions for the Incyte Ingenuity Award program, which aims to support the U.S. graft-versus-host disease (GVHD) community by funding novel initiatives that address challenges faced by GVHD patients, caregivers and healthcare providers. Following feedback received from the community after the award program's inaugural year in 2020, the Incyte Ingenuity Award program has been expanded in 2021 to include a $35,000 award, in addition to the original $100,000 award, to better support projects of different scales.

Award applications are welcome from non-profit 501(c)(3), patient, policy and caregiver organizations, healthcare providers and mid-level/junior faculty of healthcare organizations who apply on behalf of their organization, as well as individuals and/or other companies that partner with either a non-profit organization or a healthcare facility. All online applications submitted by the deadline of June 30, 2021 will be reviewed by an independent judging panel comprised of Gerry Cowden, Founder, Meredith Cowden Foundation, Shrina Duggal, Pharm. D., BCOP, Clinical Pharmacy Specialist, and Navneet Majhail, M.D., Director, Blood and Marrow Transplant Program, Cleveland Clinic, along with two new judges. The top three candidates per award selected by the judging panel will move to the final application round.

Visit [http://www.incyteingenuityawards.com/](http://www.incyteingenuityawards.com/) to learn more about the award program’s eligibility criteria and submit an online application.

**About GVHD**
GVHD is a condition that can occur after an allogeneic stem cell transplant (the transfer of stem cells from a donor) in which
the donated cells initiate an immune response and attack the transplant recipient’s organs, leading to significant morbidity and mortality. There are two major forms of GVHD: acute, which generally occurs within 100 days of transplant, and chronic, which generally occurs after 100 days of transplant\(^1\). Both forms can affect multiple organ systems, including the skin, gastrointestinal (digestive) tract and liver.

**About Incyte**
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit [Incyte.com](http://Incyte.com) and follow [@Incyte](https://twitter.com/@Incyte).

---

**Incyte Media Contacts:**

Jenifer Antonacci  
Senior Director, Public Affairs  
Tel: +1 302 498 7036  
[jantonacci@incyte.com](mailto:jantonacci@incyte.com)

Kristen Griffiths  
Senior Manager, Public Affairs  
Tel: +1 302 498 7012  
[kgriffiths@incyte.com](mailto:kgriffiths@incyte.com)

---